| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ludwig Institute for Cancer Research, Austin & Repatriation Medical Centre, Heidelberg, Victoria, Australia
Correspondence: Ian D. Davis, Ludwig Institute for Cancer Research, Austin & Repatriation Medical Centre, Studley Rd., Heidelberg, Victoria 3084, Australia. E-mail: Ian.Davis{at}ludwig.edu.au
Over most of the 20th century, immunotherapy for cancer was based on empiricism. Interesting phenomena were observed in the areas of cancer, infectious diseases, or transplantation. Inferences were made and extrapolated into new approaches for the treatment of cancer. If tumors regressed, the treatment approaches could be refined further. However, until the appropriate tools and reagents were available, investigators were unable to understand the biology underlying these observations. In the early 1990s, the first human tumor T cell antigens were defined and dendritic cells were discovered to play a pivotal role in antigen presentation. The current era of cancer immunotherapy is one of translational research based on known biology and rationally designed interventions and has led to a rapid expansion of the field. The beginning of the 21st century brings the possibility of a new era of effective cancer immunotherapy, combining rational, immunological treatments with conventional therapies to improve the outcome for patients with cancer.
Key Words: review • vaccines • dendritic cells • T cells • antigens • peptides
This article has been cited by other articles:
|
|
 |
|
  S. J. A. M. Santegoets, H. J. Bontkes, A. G. M. Stam, F. Bhoelan, J. J. Ruizendaal, A. J. M. van den Eertwegh, E. Hooijberg, R. J. Scheper, and T. D. de Gruijl Inducing Antitumor T Cell Immunity: Comparative Functional Analysis of Interstitial Versus Langerhans Dendritic Cells in a Human Cell Line Model J. Immunol., April 1, 2008; 180(7): 4540 - 4549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Krause, E. Singer, P. I. Darley, J. Klebensberger, M. Groettrup, and D. F. Legler Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO J. Leukoc. Biol., November 1, 2007; 82(5): 1106 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Gogolak, B. Rethi, I. Szatmari, A. Lanyi, B. Dezso, L. Nagy, and E. Rajnavolgyi Differentiation of CD1a- and CD1a+ monocyte-derived dendritic cells is biased by lipid environment and PPAR{gamma} Blood, January 15, 2007; 109(2): 643 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Klinke II An age-structured model of dendritic cell trafficking in the lung. Am J Physiol Lung Cell Mol Physiol, November 1, 2006; 291(5): L1038 - L1049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kovar, O. Boyman, X. Shen, I. Hwang, R. Kohler, and J. Sprent Direct stimulation of T cells by membrane vesicles from antigen-presenting cells PNAS, August 1, 2006; 103(31): 11671 - 11676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Barrow, J. Browning, D. MacGregor, I. D. Davis, S. Sturrock, A. A. Jungbluth, and J. Cebon Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage Clin. Cancer Res., February 1, 2006; 12(3): 764 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Lopez, S. K. Adris, A. I. Bravo, Y. Chernajovsky, and O. L. Podhajcer IL-12 and IL-10 Expression Synergize to Induce the Immune-Mediated Eradication of Established Colon and Mammary Tumors and Lung Metastasis J. Immunol., November 1, 2005; 175(9): 5885 - 5894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schnurr, Q. Chen, A. Shin, W. Chen, T. Toy, C. Jenderek, S. Green, L. Miloradovic, D. Drane, I. D. Davis, et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery Blood, March 15, 2005; 105(6): 2465 - 2472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Vitale, G. Pelusi, B. Taroni, G. Gobbi, C. Micheloni, R. Rezzani, F. Donato, X. Wang, and S. Ferrone HLA Class I Antigen Down-Regulation in Primary Ovary Carcinoma Lesions: Association with Disease Stage Clin. Cancer Res., January 1, 2005; 11(1): 67 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. O'Neill, S. Adams, and N. Bhardwaj Manipulating dendritic cell biology for the active immunotherapy of cancer Blood, October 15, 2004; 104(8): 2235 - 2246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Chen, H. Jackson, P. Parente, T. Luke, M. Rizkalla, T. Y. Tai, H.-C. Zhu, N. A. Mifsud, N. Dimopoulos, K.-A. Masterman, et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant PNAS, June 22, 2004; 101(25): 9363 - 9368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Paczesny, J. Banchereau, K. M. Wittkowski, G. Saracino, J. Fay, and A. K. Palucka Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells J. Exp. Med., June 7, 2004; 199(11): 1503 - 1511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. DeLong, T. Tanaka, R. Kruklitis, A. C. Henry, V. Kapoor, L. R. Kaiser, D. H. Sterman, and S. M. Albelda Use of Cyclooxygenase-2 Inhibition to Enhance the Efficacy of Immunotherapy Cancer Res., November 15, 2003; 63(22): 7845 - 7852. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
